Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2001

01-09-2001

Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?

Authors: S. Kasimir-Bauer, C. Oberhoff, K. Sliwinska, R. Neumann, A.E. Schindler, S. Seeber

Published in: Breast Cancer Research and Treatment | Issue 2/2001

Login to get access
Metadata
Title
Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use?
Authors
S. Kasimir-Bauer
C. Oberhoff
K. Sliwinska
R. Neumann
A.E. Schindler
S. Seeber
Publication date
01-09-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1012288201969

Other articles of this Issue 2/2001

Breast Cancer Research and Treatment 2/2001 Go to the issue

OriginalPaper

Expression of E2F-1 and E2F-4 is reduced in primary and metastatic breast carcinomas*

OriginalPaper

Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease

OriginalPaper

Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy

OriginalPaper

Early-stage breast cancer treatment among medically underserved women diagnosed in a national screening program, 1992–1995

OriginalPaper

Clinical management of women with genomic BRCA1 and BRCA2 mutations*

Instructions for Authors

Instructions for authors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits